<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025722</url>
  </required_header>
  <id_info>
    <org_study_id>DS1211-A-U104</org_study_id>
    <nct_id>NCT05025722</nct_id>
  </id_info>
  <brief_title>Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings</brief_title>
  <official_title>An Evaluation of Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PXE International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This PXE biomarker study aims to characterize the levels of inorganic pyrophosphate (PPi),&#xD;
      pyridoxal 5´-phosphate (PLP), and other biomarkers relevant to PXE and ectopic calcification&#xD;
      in both PXE patients and their biological siblings who are PXE carriers or normal non-PXE&#xD;
      individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional PXE study is designed to assess differences in circulation levels of&#xD;
      selective biomarkers related to PXE and tissue-nonspecific alkaline phosphatase (TNAP)&#xD;
      inhibition, between PXE patients, PXE carriers, and non-PXE normal individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 30, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Plasma Levels of Inorganic Pyrophosphate (PPi)</measure>
    <time_frame>Study visit (0 up to 2 hours)</time_frame>
    <description>PPi will be assessed by study group and by timepoint where applicable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Plasma Levels of Pyridoxal 5´-Phosphate (PLP)</measure>
    <time_frame>Study visit (0 up to 2 hours)</time_frame>
    <description>PLP will be assessed by study group and by timepoint where applicable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Serum Enzyme Activity Levels of Alkaline Phosphatase (ALP)</measure>
    <time_frame>Study visit (0 up to 2 hours)</time_frame>
    <description>ALP will be measured using the standard clinical chemistry assays, by study group and by timepoint where applicable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Serum Enzyme Activity Levels of Bone-specific Alkaline Phosphatase (BSAP)</measure>
    <time_frame>Study visit (0 hours)</time_frame>
    <description>BSAP will be measured using the standard clinical chemistry assays, by study group and by timepoint where applicable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Plasma Levels of PPi and PLP, by Sex</measure>
    <time_frame>Study visit (0 to 2 hours)</time_frame>
    <description>Blood samples will be assessed by sex group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Serum Enzyme Activity of ALP, by Sex</measure>
    <time_frame>Study visit (0 to 2 hours)</time_frame>
    <description>Blood samples will be assessed by sex group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline and Variability in Plasma Levels of PPi and PLP</measure>
    <time_frame>Study visit (0 to 2 hours)</time_frame>
    <description>Variability of PPi and PLP will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline and Variability in Serum Enzyme Activity of ALP</measure>
    <time_frame>Study visit (0 to 2 hours)</time_frame>
    <description>Variability of ALP will be assessed.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pseudoxanthoma Elasticum</condition>
  <arm_group>
    <arm_group_label>Confirmed PXE participants</arm_group_label>
    <description>Participants who have index PXE/proband with established PXE and ABCC6 mutations identified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXE carrier participants</arm_group_label>
    <description>Participants who are biological siblings of the PXE index case and confirmed as PXE carrier.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-PXE normal participants</arm_group_label>
    <description>Participants who are biological siblings of PXE index case and confirmed as non-PXE normal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non Interventional</intervention_name>
    <description>This is an observational study.</description>
    <arm_group_label>Confirmed PXE participants</arm_group_label>
    <arm_group_label>Non-PXE normal participants</arm_group_label>
    <arm_group_label>PXE carrier participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PXE probands with identified ABCC6 mutations and non-PXE biological siblings will be&#xD;
        invited for study participation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants aged 18 to 75 years&#xD;
&#xD;
          -  Participants (approximately 1 carrier and 1 normal to match proband)&#xD;
&#xD;
               -  Confirmed PXE participants: index PXE/proband with established PXE and ABCC6&#xD;
                  mutations identified&#xD;
&#xD;
               -  PXE carrier participants: biological sibling of the PXE index case and confirmed&#xD;
                  as PXE carrier&#xD;
&#xD;
               -  Non-PXE normal participants: biological sibling of PXE index case and confirmed&#xD;
                  as non-PXE normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unconfirmed ABCC6 mutation status&#xD;
&#xD;
          -  Use of bisphosphonate in the preceding 12 months and during the study&#xD;
&#xD;
          -  Use of Vitamin B6 and/or Vitamin D supplement in the preceding 1 month and during the&#xD;
             study (if the total Vitamin B6 supplementation is &gt;5 mg/day)&#xD;
&#xD;
          -  Recent initiation or dose change of Vitamin D and/or multivitamin supplement in the&#xD;
             preceding 1 month and during the study&#xD;
&#xD;
          -  Bone fracture within 3 months prior to Screening or active bone disease (excluding&#xD;
             osteopenia or osteoporosis)&#xD;
&#xD;
          -  History of hyperparathyroidism&#xD;
&#xD;
          -  History of moderate to severe renal impairment&#xD;
&#xD;
          -  History of hypophosphatasia&#xD;
&#xD;
          -  Known history of uncorrected abnormality in calcium (Ca), phosphate, alkaline&#xD;
             phosphatase (ALP) or parathyroid hormone&#xD;
&#xD;
          -  Other significant condition (medical, psychiatric, social, or medication) that, in the&#xD;
             judgment of the Investigator, would prevent full participation or would be&#xD;
             inappropriate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daiichi Sankyo Contact for Clinical Trial Information</last_name>
    <phone>908-992-6400</phone>
    <email>CTRinfo@dsi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pseudoxanthoma Elasticum</keyword>
  <keyword>Bone turnover biomarkers</keyword>
  <keyword>Tissue mineralization biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoxanthoma Elasticum</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

